Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
51 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ovid Therapeutics Inc.’s names, not what it holds today.
Patents granted
51
51 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 5 in 2024 and 5 in 2023
Applications published
125
8 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals19
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Ovid Therapeutics Inc. its own name
named as the applicant on its applications, in US
124 publishedOVID THERAPEUTICS INC. its own name
US, as the owner printed on each patent
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 11, 2025 | 12,465,597 | Methods of treating developmental disorders with gaboxadol | Pharmaceuticals | OVID THERAPEUTICS INC. |
| Apr 29, 2025 | 12,285,397 | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders | Pharmaceuticals | OVID THERAPEUTICS INC. |
| Nov 19, 2024 | 12,144,801 | Methods and compositions for treatment of epileptic disorders | Pharmaceuticals | OVID THERAPEUTICS INC. |
| Oct 8, 2024 | 12,109,201 | Methods and compositions for treatment of epileptic disorders | Pharmaceuticals | OVID THERAPEUTICS INC. |
| Mar 5, 2024 | 11,918,563 | Methods and compositions for treatment of epileptic disorders | Pharmaceuticals | OVID THERAPEUTICS INC. |
| Mar 5, 2024 | 11,918,551 | Methods of treating seizure disorders and Prader-Willi syndrome | Pharmaceuticals | OVID THERAPEUTICS INC. |
| Feb 20, 2024 | 11,903,930 | Methods and compositions for treatment of epileptic disorders | Pharmaceuticals | OVID THERAPEUTICS INC. |
| Nov 7, 2023 | 11,806,336 | Methods and compositions for treatment of epileptic disorders | Pharmaceuticals | OVID THERAPEUTICS INC. |
| Oct 3, 2023 | 11,771,671 | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction | Pharmaceuticals | OVID THERAPEUTICS INC. |
| Sep 19, 2023 | 11,761,006 | Use of MIR101 or MIR128 in the treatment of seizure disorders | Pharmaceuticals | OVID THERAPEUTICS INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 11, 2025 | 2025/0281500 | FUSED AMINO PYRIMIDINE COMPOUNDS AND PRIDOPIDINE FOR TREATMENT OF HUNTINGTON’S DISEASE | Pharmaceuticals | Ovid Therapeutics Inc. |
| Sep 11, 2025 | 2025/0281499 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF NEUROPATHIC AND NEURO-INFLAMMATORY PAIN | Pharmaceuticals | Ovid Therapeutics Inc. |
| Sep 11, 2025 | 2025/0281498 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF SYNUCLEINOPATHIES AND TDP-43 PROTEINOPATHIES | Pharmaceuticals | Ovid Therapeutics Inc. |
| Sep 11, 2025 | 2025/0281497 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF SEIZURE DISORDERS | Pharmaceuticals | Ovid Therapeutics Inc. |
| Jun 19, 2025 | 2025/0195459 | USE OF (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, MENIERE’S DISEASE, TOURETTE’S SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND ADDICTION | Pharmaceuticals | Ovid Therapeutics Inc. |
| Mar 6, 2025 | 2025/0073214 | USE OF GABOXADOL FOR THE TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER | Pharmaceuticals | Ovid Therapeutics Inc. |
| Jan 23, 2025 | 2025/0025449 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS | Pharmaceuticals | Ovid Therapeutics Inc. |
| Jan 23, 2025 | 2025/0025448 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | Pharmaceuticals | Ovid Therapeutics Inc. |
| Dec 19, 2024 | 2024/0415817 | METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS | Pharmaceuticals | Ovid Therapeutics Inc. |
| Dec 12, 2024 | 2024/0409945 | RNAi TARGETING PPP2R5D MISSENSE MUTATIONS FOR TREATMENT OF JORDAN’S SYNDROME | Biotechnology | Ovid Therapeutics Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 17 · Biotechnology 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.